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Abstract
The human immunodeficiency virus type 1 (HIV-1) external envelope glycoprotein gp120 presents conserved
binding sites for binding to the primary virus receptor CD4 as well as the major HIV chemokine coreceptors, CCR5
and CXCR4.
Concerted efforts are underway to understand the specific interactions between gp120 and coreceptors as well as
their contribution to the subsequent membrane fusion process.
The present review summarizes the current knowledge on this biological aspect, which represents one of the key
and essential points of the HIV-host cell interplay and HIV life cycle. The relevance of conformational HIV-1
Envelope proteins presented on Virus-like Particles for appropriate assessment of this molecular interaction, is also
discussed.
Introduction
The molecular interaction between HIV-1 gp120, in its
trimeric conformation, and the CD4 receptor on the
host cell surface represents the first step of the HIV
infection cycle. Upon this interaction, the co-receptor-
binding site on the gp120 is exposed, enabling the bind-
ing to HIV chemokine coreceptors (mainly CCR5 or
CXCR4) expressed on the surface of a subset of CD4+
lymphocytes. The binding to the coreceptors is followed
by fusion of the viral and host cell membranes mediated
by the HIV gp41 transmembrane glycoprotein [1-6].
Dissecting the structural changes which HIV external
envelope glycoprotein gp120 molecule undergo upon
molecular interactions with its cognate cellular receptor
and coreceptors, provide essential information to the
development of HIV-1-specific drugs, targeting the viral
entry step [7-16], as well as of vaccines [17-20].
Gp120 binding to chemokine coreceptors
The HIV-1 Envelope is synthesized as the polyprotein
precursor gp160, which undergoes oligomerization, dis-
ulfide bond formation and extensive glycosylation in the
endoplasmic reticulum [21]. The full post-translational
processing and maturation lead to proteolytical cleavage
of precursor gp160 into the surface gp120 and trans-
membrane gp41 subunits by furin-like endo-proteases in
the Golgi network [22-24]. The two subunits will assem-
ble into a trimer consisting of three gp120 molecules
associated non-covalently with three gp41 subunits.
The molecular interaction of HIV gp120 with the CD4
receptor and, subsequently, with the CCR5 or CXCR4
coreceptor leads to the insertion of the hydrophobic
gp41 N-terminal region (fusion peptide) into the host
cell membrane. In particular, the gp41 ectodomain tri-
mer acquires the six-helix bundle configuration which
drives in close contact the viral and cell membranes,
ultimately resulting in their fusion [1,2,4,25,26]. There-
fore, the binding of HIV envelope to cellular coreceptors
dramatically influence the strength of viral-cell interac-
tion and promote the conformational changes in the
gp41 required to overcome the energy barrier and
induce pore formation and membrane fusion.
Within the CCR5 and CXCR4 amino acid residues
interacting with the gp120, most of the cysteine residues
are involved in disulfide bonds formation and play a key
functional role. In particular, the N-terminal and second
extracellular domain (ECII) of both coreceptors seem to
be critical for gp120-CD4 complex binding [27-35].
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The role of coreceptors in the conformational changes
of the HIV transmembrane gp41 to facilitate virus-cell
membrane fusion has not yet been fully clarified, mainly
due to the lack of the CCR5 and CXCR4 crystal struc-
ture and, therefore, their absence in high resolution
X-ray structures solved for CD4-bound gp120 [17]. The
currently accepted theory proposes that, upon the core-
ceptor binding to the gp120-CD4 complex, the gp41
acquires the thermostable, six-helix bundle structure
that brings the two membranes together and results in
fusion pore formation [36,37].
The first step is the exposure of the hydrophobic fusion
peptide at the N terminus of gp41 which interacts with
the target cell membrane, generating an intermediate,
pre-hairpin state bridging the virus and cell membranes.
The pre-hairpin then refolds into the stable, six-helix
bundle core structure [38,39], releasing sufficient energy
to overcome the kinetic barrier [40,41] and catalyzing the
fusion of the two membranes [42]. Whether the fusion
can occur with the free energy liberated during refolding
of one or several trimers, is still debated [40,43] (Fig.1).
In the described stepwise process, the pre-hairpin state
shows a relatively long half-life [44], representing a
favorable target for inhibitory peptides [45,46] as well as
neutralizing antibodies specific for the gp41 HR1 and
MPER regions [47-50].
Several data about the envelope/receptor interactions
have been generated also for the simian counterpart of
HIV (Simian Immunodeficiency Virus, SIV). Indeed,
SIVmac is the natural etiological agent of the AIDS-like
syndrome in Rhesus Macaques, which is the only avail-
able animal model for obtaining relevant information
on AIDS pathogenesis [51-54] as well as for testing
efficacy of antiviral therapeutics and vaccine candidates
[55,56].
Similarly to HIV-1, SIV infection starts with the high-
affinity interaction of the gp120-gp41 envelope glycopro-
tein (Env) complex with CD4 on the target cell surface
[57,58]. However, in contrast to HIV-1, different strains
of SIV preferentially use CCR5 and not CXCR4 as
coreceptor for entry [59-61], although they may show
promiscuity in coreceptor usage, engaging alternative
Figure 1 Dissection of sequential steps occurring after engagement of receptor and coreceptor by trimeric HIV envelope proteins.
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coreceptors GPR15 and CXCR6/STRL33 with high effi-
ciency [62,63].
Moreover, SIV strains have been shown to infect tar-
get cells via a CD4-independent pathway, directly inter-
acting with CCR5 or CXCR4 coreceptor [64,65]. It has
been proposed that Env protein of such strains contains
multiple amino acid substitutions leading to the consti-
tutive exposure of coreceptor binding site [66,67], simi-
larly to what described for CD4-independent HIV-1
envelope proteins [68,69]. As consequence, CD4-inde-
pendent viruses acquire a broader cell tropism, being
able to infect also CD4 negative or low-expressing cells,
such as macaque macrophages [70,71].
The molecular interaction of SIV envelope protein
with the CD4 receptor and coreceptors leads to confor-
mational changes in the gp41 ectodomain trimers and
exposure of the fusion peptide which closely resemble
what described for the HIV-1 counterpart [72,73].
Role of coreceptors post-translational modifications in
HIV-1-mediated cell fusion
The effectiveness of CCR5 and CXCR4 as HIV corecep-
tors depends on the several possible conformations
which may significantly influence their ability to support
viral entry in different cells [74,75].
Furthermore, post-translational modifications of HIV
coreceptors and, in particular, of the extracellular
domains (including the N-terminal, EC I – III) and
intracellular loops, may modulate the receptor turnover
as well as the binding efficacy to the HIV gp120. In
general, extracellular domains may undergo N-linked or
O-linked glycosylation and tyrosine sulfation, while
modifications of intracellular loops include palmitoyla-
tion, phosphorylation, and ubiquitination [76-79].
CCR5. The CCR5 N-terminal is relevant for the role
as HIV-1 coreceptor [27,29,30] and contains several
tyrosine residues which may be modified by sulfation,
contributing to binding to natural ligands (MIP1-a,
MIP1-b) as well as HIV-1 gp120-CD4 complexes
[80-82]. In particular, sulfation of Tyrosines at position
10 and 14 seems to be a requisite for the CCR5 binding
efficacy [83,84]. Moreover, CCR5 is also modified by
O-linked glycosylation, preferentially on Ser-6 [85,86],
although it does not seem to affect the role of CCR5 in
the HIV entry [86].
As most chemokine receptors, the CCR5 carboxyl-
terminus contains one or more cysteine residues compa-
tible with receptor palmitoylation, typically located 12 to
25 amino acids away from the plasma membrane
boundary [87]. Cysteine residues at amino acid positions
321, 323, and 324 undergo to palmitoylation, facilitating
the CCR5 transport to the plasma membrane as well as
ligand-stimulated endocytosis and affecting its ability to
initiate intra-cellular signalling pathways [88-90].
However, the biological role of improved localization of
CCR5 to lipid rafts for HIV entry into host cells is still
disputed [88-92].
CXCR4. Similar to CCR5, also CXCR4 undergo post-
translational modifications contributing to its function.
CXCR4 is sulfated at three tyrosine residues in the
N-terminus, with Tyr21 accounting for the majority of
sulfate incorporation, although this modification doesn’t
appear to modulate the CXCR4 coreceptor function for
HIV-1 [83].
In contrast to CCR5, the extracellular domain of
CXCR4 is post-translationally modified by N-linked gly-
cosylation in two potential sites, Asn11 and Asn176
[93,94], although only Asn11 appears to be glycosylated
in mammalian cells [94]. Mutation of Asn11 does not
impair the CXCR4-mediated HIV-1 infection [95,96];
however, a Asn11-to-Glu11 mutation leads to enhanced
binding of both CXCR4-specific and dual-tropic (CCR5
and CXCR4) HIV-1 isolates [78,96].
HIV-1 Envelope-coreceptor signaling
The binding of the gp120-CD4 complex to chemokine
coreceptors not only mediates HIV entry but also acti-
vates intracellular signaling cascades, mimicking chemo-
kine signaling induced by binding to cognate receptors
[97,98] (reviewed in [77,99,100].
However, in addition to signaling pathways mediating
cell migration, transcriptional activation, cell growth and
differentiation [101-106], binding of gp120-CD4 com-
plex to CCR5 or CXCR4 coreceptor has also been
shown to trigger the activation of proline-rich tyrosine
kinase (Pyk2), phosphoinositide 3-kinases (PI3K)
[107,108] and CD4/CXCR4-dependent NFAT (nuclear
factor of activated T cells) nuclear translocation [109].
Furthermore, gp120 was demonstrated to mediate che-
motaxis, actin cytoskeleton rearrangement [108], and
the activation of an actin depolymerization factor, cofi-
lin, to increase the cortical actin dynamics in resting
CD4 T cells [110]. (For a more comprehensive descrip-
tion of gp120-triggered chemokines coreceptor signaling,
refer to Cicala and Arthos in this same supplement).
Stable trimeric forms of human immunodeficiency
virus recombinant gp140
As described above, the envelope proteins on the virus
surface are assembled into trimers, consisting of three
gp120 molecules associated non-covalently with three
gp41 subunits, which interact sequentially with the CD4
receptor and the chemokine coreceptors, ultimately
leading to viral and cell membrane fusion. In the last
years, mainly aiming at inducing more potent and
broader anti-HIV neutralizing antibodies, several groups
have been developing soluble trimers of the gp120 -
gp41 Env ectodomain (i.e., lacking the transmembrane,
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cytoplasmic domains and named gp140) which are con-
sidered to preserve or mimic the structure of functional
Env complexes [111-114]. Considering the close struc-
tural similarity of these molecules to native trimeric
HIV Envelope proteins, this can represent a relevant
tool also for receptor and chemokines coreceptor bind-
ing studies.
Mutations in the furin cleavage site at the gp120–gp41
junction inhibit the dissociation between the two envel-
ope subunits [114-117], but cleavage-defective gp140
Env proteins seem to be antigenically different from
fully processed Env [118-120]. In order to express pro-
cessed and stable trimers of gp140, an intermolecular
disulfide bond has been introduced between the gp120
and gp41 subunits to form a complex called “SOS”
gp140 which, although still predominantly monomeric,
strongly reacts with the broadly neutralizing b12mAb
[118]. An isoleucine-to-proline substitution introduced
at position 559 in the N-terminal heptad region of gp41
has been shown to increase the stability of SOS gp140
(SOSIP gp140), leading to a fully cleaved and trimeric
structure with optimal antigenic properties [121,122].
Moreover, cleavage-defective gp140 Env proteins have
been further modified at the C-terminus to improve
trimer formation and stabilization, fusing different
heterologous trimerization motifs. In particular, a 32-
amino-acid form of the GCN4 transcription factor
(GCN), a 27-amino-acid trimerization domain from the
C-terminus of bacteriophage T4 fibritin (T4F), or a solu-
ble trimerization domain of chicken cartilage matrix
(CART) protein have been employed, showing enhanced
binding to broadly neutralizing b12 and 2G12 mAbs
[115,116,123]. More recently, the effectiveness of the
catalytic chain of aspartate transcarbamoylase (ATCase)
as trimerization domain for the HIV gp140 has been
described [124,125].
Exploiting the VLP model
In addition to soluble forms, HIV gp140 trimeric com-
plex can be presented on membrane structures includ-
ing liposomes, inactivated viruses and virus-like particles
(VLPs) or pseudovirions, to mimic as close as possible
the native conformation [126-131].
In particular, Virus-like particles (VLPs) represent a
complex structure based on viral capsid proteins which
self-assemble into particulate structures closely resem-
bling immature virus particles [132-135]. VLPs are
replication as well as infection incompetent, lacking reg-
ulatory proteins as well as infectious genetic material,
and can be considered nanoparticles and employed
to deliver antigenic structures as well as DNA molecules
to antigen presenting cells, for enhanced induction of
immune responses against co-administered plasmid
DNA-based immunogens [136-140].
VLPs have been produced from a broad spectrum of
non-enveloped and enveloped viruses [140]. In particu-
lar, the particle structure of non-enveloped VLPs can be
based on single or multiple capsid proteins without a
surrounding cell membrane. Examples of such VLPs are
those formed by the expression of the major capsid pro-
tein of papillomaviruses, parvoviruses and polyoma-
viruses [135,141-143] or by multiple interacting capsid
proteins of Reoviridae family [144]. Alternative strategy
for generating non-enveloped virus-like-particles (VLPs)
is based on the assembly of the capsid protein derived
from RNA bacteriophages [145-147].
Alternatively, enveloped VLPs are based on assembled
capsid proteins surrounded by cell membrane and have
been developed for enveloped viruses such as hepatitis B
and C virus (HBV & HCV), influenza A and retro-
viruses, including HIV-1 [129,132,133,148-152].
The different forms of VLPs have distinct properties
for displaying antigens, given that only enveloped VLPs
may display full-length monomeric or multimeric
conformational proteins on their surface through trans-
membrane domains [129-131,153]. Non-enveloped
VLPs, on the contrary, may be employed to present
mainly short peptides or protein sequences. This has
been achieved either generating chimeric capsid proteins
expressing foreign epitope in frame (eg. Gag:V3)
[154-157], or chemically linking the foreign epitope to
the assembled capsid protein [158], although HIV-1 Gag
proteins fused to full-length HIV Reverse Transcriptase
(RT) protein, without loosing the capability of assem-
bling into VLPs, have been recently reported [159]. The
conformational structure of full-length proteins possibly
expressed on non-enveloped VLPs, however, remains to
be proven.
As consequence, at present, only enveloped VLPs
displaying full-length conformational proteins on their
surface may be a suitable experimental model for studies
on binding and interaction between HIV envelope and
cellular receptor/coreceptors. They, indeed, represent
the closest particle structure to native virus.
Conformational HIV Envelopes presented on particulate
structures
Development of HIV-1 Pr55Gag-based VLPs expressing
gp120/gp140 trimeric Envelope proteins is a goal pur-
sued by several Groups, using different expression sys-
tems (mammalian vs baculovirus) as well as different
trans-membrane domains. In particular, our group has
previously developed Pr55gag-VLPs presenting a gp120
anchored through the trans-membrane (TM) portion of
the Epstein-Barr virus (EBV) gp220/350, showing the
formation of oligomeric structures [129] and inducing
Env-specific humoral and cellular immune response
[160-162]. Additional strategies have been more recently
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described to express trimeric forms of HIV-1 gp140
molecules on the surface of Pr55gag-VLPs [130,131].
Comparative studies showed that specific trans-
membrane domains induced optimal incorporation of
gp140 Env trimers onto VLP surface, retaining con-
served epitopes and undergoing conformational changes
upon CD4 binding [131] (Buonaguro et al., submitted).
Considering the biological and structural properties of
HIV gp140 trimers presented on the VLP surface, they
can be even more strategic for binding studies, provid-
ing an invaluable tool for evaluating and dissecting the
whole virus-host cell interaction leading to and ending
with membrane fusion [163,164] (Fig. 2).
Conclusions
The interaction between HIV particles and target host
cells is a defined temporally sequential stepwise process,
characterized by the binding of surface gp120 Envelope
protein to CD4 receptor and subsequent binding of the
gp120-CD4 complex to chemokines coreceptors. This
will ultimately lead to membrane fusion and host cell
infection.
Studies aimed at dissecting the sequential steps of this
process have been and will be instrumental not only to
fully understand the strategies adopted by HIV to hijack
host cells for its own replication but also to develop
HIV-1-specific drugs and vaccines.
The development of novel and improved molecular
tools, mimicking as close as possible native Envelope tri-
meric structures expressed on non-infectious particulate
structures (i.e. VLPs), will expand the armamentarium
for HIV-host cell interaction studies. This will help in
shedding further light on such a key moment of the
HIV infection as well as pathogenesis.
Figure 2 Schematic representation of HIV-1 gp120 binding to cellular receptor and coreceptors. The binding of HIV Envelope protein to
CD4 receptor and chemokines coreceptors on the host cell surface is represented showing the gp120 in its monomeric form (A) and trimeric
form as soluble (B) or bound to virus like particles (VLPs) (C).
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